A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

Lung cancer is the most common human malignancy and leads to about one-third of all cancer-related deaths. Lung adenocarcinomas harboring KRAS mutations, in contrast to those with EGFR and EML4-ALK mutations, have not yet been successfully targeted. Here, we describe a combination therapy for treati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Xia, Yifeng, Liu, Yi-Liang, Xie, Yonghua, Zhu, Wei, Guerra, Francisco, Shen, Shen, Yeddula, Narayana, Fischer, Wolfgang, Low, William, Zhou, Xiaoying, Zhang, Yonghui, Oldfield, Eric, Verma, Inder M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326221/
https://ncbi.nlm.nih.gov/pubmed/25411474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3010382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados